Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Concepts in Ras-directed therapy.

Kloog1, Cox, Sinensky

  • 1Department of Neurobiochemistry, The George S Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv 69978, Israel. kloog@ccsg.tau.ac.il

Expert Opinion on Investigational Drugs
|January 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary embolism.

The Broadway·2010
Same author

The Potential of SERMs for Reducing the Risk of Coronary Heart Disease.

Trends in endocrinology and metabolism: TEM·2001
Same author

Reducing seat dip attenuation

The Journal of the Acoustical Society of America·2000
Same author

Anesthesia and Intensive Care for Organ Transplantation.

Intensive & critical care nursing·2000
Same author

Lymphatic Mapping: A Technique Providing Accurate Staging for Breast Cancer.

Breast cancer (Tokyo, Japan)·2000
Same author

One-dimensional pattern formation with galilean invariance near a stationary bifurcation

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Ras proteins are crucial for cell signaling, and their aberrant function drives cancer. New therapies target Ras, including farnesyltransferase inhibitors (FTIs) and compounds disrupting Ras interactions, showing promise in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Ras proteins are central to growth factor signaling pathways, regulating cell growth and differentiation.
  • Dysregulated Ras signaling, often due to activating mutations, is implicated in a significant percentage of human cancers.
  • Understanding Ras post-translational modifications, activation/inactivation mechanisms, and effector interactions is key for developing targeted therapies.

Purpose of the Study:

  • To review progress in developing Ras-directed cancer therapies.
  • To highlight novel therapeutic strategies beyond farnesyltransferase inhibitors (FTIs).
  • To discuss emerging concepts for targeting oncogenic Ras and enhancing anti-tumor immunity.

Main Methods:

  • Review of current literature on Ras-targeted therapies.

Related Experiment Videos

  • Discussion of farnesyltransferase inhibitors (FTIs) and their clinical trial status.
  • Exploration of alternative strategies including S-farnesylthiosalicylic acid (FTS), effector interaction inhibitors, and novel GTPase-activating concepts.

    • Main Results:

    • Farnesyltransferase inhibitors (FTIs) are the most advanced Ras-directed therapy, with ongoing clinical trials.
    • Compounds like S-farnesylthiosalicylic acid (FTS) demonstrate efficacy in disrupting Ras membrane anchorage and inhibiting tumor growth in preclinical models.
    • Novel approaches are emerging, including drugs to restore Ras GTPase activity and reovirus-mediated tumor regression in Ras-dependent cancers.

    Conclusions:

    • Ras remains a critical target for cancer drug development due to its central role in oncogenesis.
    • Multiple therapeutic strategies targeting Ras are progressing, offering new hope for cancer treatment.
    • Future directions include restoring Ras function, targeting its interactions, and leveraging viral therapies for enhanced anti-tumor effects.